Galmed Announces Successful First-in-Human Proof-of-Concept Clinical Study Results for Colospan's Novel Intraoperative Tissue Assessment Technology
Go back to Galmed Announces Successful First-in-Human Proof-of-Concept Clinical Study Results for Colospan's Novel Intraoperative Tissue Assessment Technology| GALMED PHARMACEUTIC (NASDAQ: GLMD) | Delayed: 3.88 -0.04 (1.02%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.92 | 52 Week High | $9.70 | |||
| Open | $4.07 | 52 Week Low | $2.78 | |||
| Day High | $4.23 | P/E | N/A | |||
| Day Low | $3.88 | EPS | $0.00 | |||
| Volume | 4,100 | |||||
